The size of the Acute Ischemic Stroke Treatment & Diagnosis Market in Europe is predicted to be worth USD 1075.60 million by 2026 from USD 796.21 million in 2021 and is estimated to be growing at a CAGR of 6.2% from 2021 to 2026.
Acute Ischemic stroke can be defined as loss of function in certain parts of the brain due to a lack of blood supply to the brain.
The rise in prevalence of acute ischemic stroke due to sedentary lifestyle, physical inactivity, poor diet, smoking, obesity is majorly driving the Ischemic stroke diagnosis and treatment market in the European region. Also, due to the increasing population to increase in the prevalence of chronic diseases such as diabetes is boosting the market growth. In addition, the rising advancements in technology for developing innovative and effective treatments for diagnosing acute ischemic stroke are increasing the demand for the products in the market.
On the other hand, the growing preferences for minimally invasive procedures accelerate the market's demand for acute ischemic stroke diagnosis and treatment. Furthermore, an increase in the investments by the government and private organizations in research activities for developing effective diagnosing devices and therapies is proving lucrative growth opportunities for the market growth. In addition, the government takes the initiative to establish medical and healthcare infrastructure in the region. The increase in awareness about the presence of treatment and medication available in the market is further expected to fuel the market growth.
However, the increase in the high costs of the treatment and surgical procedures and the strict government rules and regulations with stringent approval procedures hampers the product's entry, which affects the market growth of the acute ischemic stroke diagnosis and treatment in the European region. In addition, a lack of awareness among the people is also limiting the market's growth. Excessive use of drugs for treating ischemic strokes also restrains the growth of acute ischemic stroke diagnosis and treatment in the market.
This research report on the European acute ischemic stroke treatment & diagnosis market has been segmented and sub-segmented into the following categories:
By Diagnostic Type:
By Surgery Type:
By Country:
Geographically, the European region is expected to hold the second-largest share in the global ischemic stroke diagnosis and treatment market during the forecast period. The regional market is growing owing to the rising population, the increasing prevalence of rising ischemic stroke cases, and older people. Also, the growing demand for diagnosing devices and effective treatment procedures for ischemic stroke diagnosis and treatment are expected to expand the market growth. Furthermore, the countries such as Germany, UK, Italy, France, and Spain are developing regional market growth.
The UK market is estimated to account for the largest share in the European market during the forecast period. The increasing initiatives from government and private organizations in research activities for developing effective and efficient diagnosing equipment are expected to propel the growth of the ischemic stroke diagnosis and treatment market.
Whereas the German market is estimated to be the fastest-growing market among the other countries in Europe. The market growth is attributed to the increase in the prevalence of ischemic disease, rising advancements in technology for developing innovative and effective treatment procedures for acute ischemic stroke, and rising demand for minimally invasive techniques for treatment.
KEY MARKET PLAYERS:
A few of the prominent companies operating in the European acute ischemic stroke diagnosis & treatment market profiled in this report are Abbott Laboratories, Covidien plc, Philips Healthcare, Johnson & Johnson, Penumbra, Inc., GE Healthcare, Siemens Healthcare, Stryker Corporation (Concentric Medical, Inc.) and Hitachi, Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Type
5.1.1 Computed Tomography
5.1.2 Magnetic Resonance Imaging
5.1.3 Ultrasound
5.1.4 Cerebral angiography
5.1.5 Nuclear Imaging
5.2 Surgery Type
5.2.1 Carotid Endarterectomy
5.2.2 Angioplasty
5.2.3 Endovascular Mechanical Thrombectomy
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Covidien plc
8.3 Johnson & Johnson
8.4 Penumbra, Inc.
8.5 Philips Healthcare
8.6 GE Healthcare
8.7 Hitachi, Ltd.
8.8 Siemens Healthcare
8.9 Stryker Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
